Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era

OBJECTIVES: Diffuse large B‐cell lymphoma (DLBCL) is an aggressive heterogeneous lymphoma with standard treatment. However, 30%‐40% of patients still fail, so we should know which patients are candidates for alternative therapies. IPI is the main prognostic score but, in the rituximab era, it cannot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Haematol
Main Authors: Gutierrez, Antonio, Bento, Leyre, Diaz‐Lopez, Antonio, Barranco, Gilberto, Garcia‐Recio, Marta, Lopez‐Guillermo, Armando, Dlouhy, Ivan, Rovira, Jordina, Rodriguez, Mario, Sanchez Pina, Jose María, Baile, Monica, Martín, Alejandro, Novelli, Silvana, Sancho, Juan‐Manuel, García, Olga, Salar, Antonio, Bastos‐Oreiro, Mariana, Rodriguez‐Salazar, Mª José, Fernandez, Ruben, de la Cruz, Fatima, Queizan, Jose Antonio, González de Villambrosia, Sonia, Cordoba, Raul, López, Andres, Luzardo, Hugo, García, Daniel, Sastre‐Serra, Jordi, Garcia, Juan Fernando, Montalban, Carlos, Cabanillas, Fernando, Rodríguez, Jose
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7217048/
https://ncbi.nlm.nih.gov/pubmed/31804029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13364
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados